Issue Information
Cancer, Volume 124, Issue 20, Page 3951-3958, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Tags: Issue Information Source Type: research
Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de ‐implementation
Cancer, Volume 124, Issue 20, Page 3971-3974, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Ted A. Skolarus,
Megan EV Caram,
Christina H. Chapman,
David C. Smith,
Brent K. Hollenbeck,
Sarah Hawley,
Alexander Tsodikov,
Anne Sales,
Daniela Wittmann,
Alexander Zaslavsky Tags: Editorial Source Type: research
Socioeconomics, race, and ethnicity in childhood cancer survival: Accessing and addressing root causes of disparities
Cancer, Volume 124, Issue 20, Page 3975-3978, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Meryl D. Colton,
Makenzie Hawkins,
DeLayna Goulding,
Myles Cockburn,
Adam L. Green Tags: Editorial Source Type: research
On the humane side of medicine
Cancer, Volume 124, Issue 20, Page 3969-3970, October 15, 2018. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Fadlo R. Khuri Tags: Editorial Source Type: research
Will my child do better if she enrolls in a clinical trial?
The question of whether children with cancer who enroll in clinical trials have superior outcomes compared with those who do not participate has been pursued for more than 4 decades, and recent studies have provided conflicting answers. Whether clinical trial participation influences outcome has important implications for how clinicians should present trial participation to patients and families. Methodological challenges limit generalizations about the impact of clinical trial participation on outcome compared with nonparticipation. Oncologists should inform patients and families that clinical trials are the engine for fu...
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Malcolm A. Smith,
Steven Joffe Tags: Commentary Source Type: research
Does socioeconomic status account for racial and ethnic disparities in childhood cancer survival?
ConclusionsSES significantly mediates racial/ethnic childhood cancer survival disparities for several cancers. However, the proportion of the total race/ethnicity –survival association explained by SES varies between black‐white and Hispanic‐white comparisons for some cancers, and this suggests that mediation by other factors differs across groups. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Rebecca D. Kehm,
Logan G. Spector,
Jenny N. Poynter,
David M. Vock,
Sean F. Altekruse,
Theresa L. Osypuk Tags: Original Article Source Type: research
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4 ‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial
ConclusionsThe sustained PFS benefit and long ‐term safety of ELd at 4 years, similar to those observed at 2 and 3 years, support ELd as a valuable therapeutic option for the long‐term treatment of patients with RRMM. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos,
Sagar Lonial,
Keith A. Betts,
Clara Chen,
Miriam L. Zichlin,
Alexander Brun,
James E. Signorovitch,
Dinara Makenbaeva,
Sabeen Mekan,
Oumar Sy,
Katja Weisel,
Paul G. Richardson Tags: Original Article Source Type: research
A prospective comparison of cancer clinical trial availability and enrollment among adolescents/young adults treated at an adult cancer hospital or affiliated children ’s hospital
ConclusionsEfforts to improve low CCT enrollment among AYAs should be differentiated by treatment site. In the adult setting, these efforts should be aimed at improving CCT availability by overcoming site ‐level barriers to opening existing CCTs. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Stefanie M. Thomas,
Jemily Malvar,
Hanh Henry Tran,
Jared T. Shows,
David R. Freyer Tags: Original Article Source Type: research
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Conclusions:Men with LAPCa or RAPCa treated initially with RP plus XRT had a lower risk of prostate cancer –specific death and improved overall survival in comparison with those men treated with XRT plus ADT, but they experienced higher rates of erectile dysfunction and urinary incontinence. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Thomas L. Jang,
Neal Patel,
Izak Faiena,
Kushan D. Radadia,
Dirk F. Moore,
Sammy E. Elsamra,
Eric A. Singer,
Mark N. Stein,
James A. Eastham,
Peter T. Scardino,
Yong Lin,
Isaac Y. Kim,
Grace L. Lu ‐Yao Tags: Original Article Source Type: research
GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers
ConclusionsIn the current sample, the genesGNAS,GNAQ, andGNA11 were widely altered across cancer types, and these alterations often were accompanied by specific genomic abnormalities inAURKA,CBL, andLYN. Therefore, targetingGNA* alterations may require drugs that address the GNA* signal and important co ‐alterations.Cancer 2018;00:000 ‐000.© 2018 American Cancer Society. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Austin J. Parish,
Vi Nguyen,
Aaron M. Goodman,
Karthikeyan Murugesan,
Garrett M. Frampton,
Razelle Kurzrock Tags: Original Article Source Type: research
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini ‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
ConclusionsThe combination of inotuzumab and low ‐intensity mini‐HCVD chemotherapy with or without blinatumomab shows encouraging results in patients with ALL in first salvage. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Elias Jabbour,
Koji Sasaki,
Farhad Ravandi,
Xuelin Huang,
Nicholas J. Short,
Maria Khouri,
Partow Kebriaei,
Jan Burger,
Joseph Khoury,
Jeffrey Jorgensen,
Nitin Jain,
Marina Konopleva,
Guillermo Garcia ‐Manero,
Tapan Kadia,
Jorge Cortes,
J Tags: Original Article Source Type: research
Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study
ConclusionsImatinib plus everolimus showed a limited activity in progressing advanced chordoma. Interestingly, the amount of tumor cells activated for mammalian target of rapamycin effectors correlated with the response. Toxicity was not negligible. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Silvia Stacchiotti,
Carlo Morosi,
Salvatore Lo Vullo,
Alessandra Casale,
Elena Palassini,
Anna Maria Frezza,
Gabriella Dinoi,
Antonella Messina,
Alessandro Gronchi,
Adalberto Cavalleri,
Elisabetta Venturelli,
Daniele Morelli,
Silvana Pilotti, Tags: Original Article Source Type: research
Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial
ConclusionsThe results of the current study suggest that although knowledge concerning the probability of having aBRCA1 and/orBRCA2 pathogenic variant remains low in this patient population, the interactive decision tool improved rates compared with a static Web site. As interest in genetic testing continues to rise, so will the need to integrate tools into the treatment decision process to improve informed decision making. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Michele C. Gornick,
Allison W. Kurian,
Lawrence C. An,
Angela Fagerlin,
Reshma Jagsi,
Steven J. Katz,
Sarah T. Hawley Tags: Original Article Source Type: research
Renal cell carcinoma and pathologic nodal disease: Implications for American Joint Committee on Cancer staging
ConclusionsAmong RCC patients classified with stage III disease, those with pT123N1M0 disease had significantly worse survival than those with pT3N0M0 disease. OS and CSS were similar for patients with pT123N1M0 disease and patients with pT123N0/xM1 disease (stage IV). If validated, these findings suggest that RCC patients with nodal disease should be reclassified as having stage IV disease. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Kai ‐Jie Yu,
Sarp K. Keskin,
Matthew A. Meissner,
Firas G. Petros,
Xuemei Wang,
Leonardo D. Borregales,
Cindy Gu,
Pheroze Tamboli,
Surena F. Matin,
Christopher G. Wood,
Jose A. Karam Tags: Original Article Source Type: research
Enrollment on clinical trials does not improve survival for children with acute myeloid leukemia: A population ‐based study
ConclusionsEnrollment on a clinical trial was not associated with improved survival for children with AML in a population ‐based cohort. Rationale for trial enrollment should not include the likelihood of benefit compared with non‐enrollment. (Source: Cancer)
Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Tony H. Truong,
Jason D. Pole,
Randy Barber,
David Dix,
Ketan P. Kulkarni,
Emilie Martineau,
Alicia Randall,
David Stammers,
Caron Strahlendorf,
Douglas Strother,
Lillian Sung Tags: Original Article Source Type: research
